Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Fig. 3

Progression free survival (PFS) and overall survival (OS) in both groups. (A) OS of all patients. The OS in the study group was significantly longer than that in the control group (20 vs. 11.5 months; P = 0.005). (B) OS of the limited-stage patients. OS in the study group was significantly longer than in the control group (26.5 vs. 11.8 months; P = 0.033). (C) PFS of the extensive-stage patients. PFS in the study group was longer than the control group (5 vs. 2.7 months; P = 0.037). (D) OS of the extensive-stage patients. OS in the study group was significantly longer than in the control group (14.5 vs. 9 months; P = 0.038)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us